Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: Placebo
DRUG: Daclatasvir
DRUG: Pegylated interferon alfa-2a
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb